Twist Bioscience Corp (TWST) reported disappointing financial results for the fourth quarter of fiscal 2025, highlighting ongoing challenges in the biotechnology sector. The company posted an earnings per share (EPS) of $-0.45, falling short of Wall Street's consensus estimate of $-0.44. Revenue for the quarter matched expectations at $0.1 billion, yet the results underscore a struggle to meet analyst forecasts.
The earnings report comes as Twist Bioscience continues to develop its proprietary semiconductor-based synthetic DNA manufacturing process. The firm specializes in creating synthetic DNA products, including synthetic genes and tools for next-generation sequencing (NGS) sample preparation. Headquartered in South San Francisco, California, Twist Bioscience employs 923 full-time staff and has a market capitalization of $1.8 billion.
Looking ahead, the company is set to host an earnings conference call to discuss these results and provide further insights into its business performance. Upcoming earnings are anticipated on August 3, 2026, with analysts estimating an EPS of $-0.35 and revenue of $114.0 million.
This update provides insight into Twist Bioscience's recent operational performance and financial health, as missing analyst expectations could reflect broader market conditions or internal challenges. Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.